| 标题 |
 Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study |
| 网址 | |
| DOI | |
| 其它 |
期刊：The Lancet. Respiratory medicine 作者：Shi Y; Chen G; Wang X; Liu Y; Wu L; et al 出版日期：2022/11/01 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时，文件已从服务器自动删除，无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
Copyright
GingerF
潇洒的惋清
魔法屎尿屁
学术文献互助
不潮薯饼
Zephyrite
无极微光
Oyama
More
Haiverxin
儒雅的板栗
称心妙竹
jenningseastera
Criminology34
学霸业
核桃
诚心香菇
Fellow_Lee
皖公网安备34019202002308
